An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients-Reference-Cited by-同舟云学术

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients

Published:2022-04-04 Issue:6 Volume:61 Page:907-918
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Wallenburg Eveline^ORCID,ter Heine Rob,Schouten Jeroen A.,Raaijmakers Jelmer,ten Oever Jaap,Kolwijck Eva,Burger David M.,Pickkers Peter,Frenzel Tim,Brüggemann Roger J. M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-022-01113-6.pdf

Reference37 articles.

1. Summary of Product Characteristics: Piperacillin/Tazobactam 4g/0.5g Powder for Solution for Infusion 2017. https://www.medicines.org.uk/emc/product/6526/smpc#gref. Accessed 7 Oct 2021.

2. Beovic B, Dousak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386–90.

3. Remschmidt C, Schneider S, Meyer E, Schroeren-Boersch B, Gastmeier P, Schwab F. Surveillance of antibiotic use and resistance in intensive care units (SARI). Dtsch Arztebl Int. 2017;114(50):858–65.

4. Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–53.

5. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http://www.eucast.org. Accessed 7 Oct 2021.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on recent analytical methodologies developed for the micro-determination of piperacillin in different matrices;Microchemical Journal;2024-10

2. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales;Antimicrobial Agents and Chemotherapy;2024-04-03

3. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals;Journal of Antimicrobial Chemotherapy;2024-03-20

4. Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin;Pharmaceutics;2024-03-04

5. Development and validation of an UPLC–MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring;Journal of Antimicrobial Chemotherapy;2024-02-28